This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Low HDL (summary and causes of)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with coronary heart disease, independent of total and low-density lipoprotein cholesterol (LDL-C) levels. Low HDL-C may be secondary to factors such as:

  • cigarette smoking
  • obesity - particularly visceral fat
  • very low fat diets e.g. vegetarian often have low HDL-C
  • drugs, including:
    • beta-adrenergic blocking agents (beta-blockers)
    • anabolic steroids such as testosterone
    • androgenic progestins

However some individuals low HDL-C levels may have a genetic, or primary, cause, including abnormalities in:

  • ApoA-I
    • complete apoA-I deficiency
    • ApoA-I mutations (eg, ApoA-I Milano)
  • lecithin:cholesterol acyl transferase (LCAT)
    • complete LCAT deficiency
    • partial LCAT deficiency (fish-eye disease)
  • ABC1
    • Tangier disease
      • homozygous
      • heterozygous
    • Familial hypoalphalipoproteinemia (some families)
  • unknown genetic aetiology
    • Familial hypoalphalipoproteinemia (most families)
    • Familial combined hyperlipidemia with low HDL-C
    • metabolic syndrome


  1. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
  2. Assmann G, von Eckardstein A, Funke H. High-density lipoproteins, reverse transport of cholesterol, and coronary artery disease: insights from mutations. Circulation. 1993;87:III-28-III-34
  3. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:425-431.
  4. Criqui MH, Wallace RB, Heiss G, et al. Cigarette smoking and plasma high-density lipoprotein cholesterol: the Lipid Research Clinics Program Prevalence Study. Circulation. 1980;62:IV70-IV76
  5. Glueck CJ, Taylor HL, Jacobs D, et al. Plasma high-density lipoprotein cholesterol: association with measurements of body mass. The Lipid Research Clinics Program Prevalence Study. Circulation. 1980;62:IV62-IV69.
  6. Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the Dietary Alternatives Study. JAMA.1997;278:1509-1515.
  7. van Brummelen P. The relevance of intrinsic sympathomimetic activity for beta-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol. 1983;5:S51-S55.
  8. Sacks FM, Gerhard M, Walsh BW. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol. 1995;6:161-166.
  9. Teran AZ, Greenblatt RB, Chaddha JS. Changes in lipoproteins with various sex steroids. Obstet Gynecol Clin North Am. 1987;14:107-119.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.